In this article, we will discuss the 10 Best 52-Week High US Stocks to Buy.
“Investors appear to be treating an end to the US-Israeli war with Iran as a foregone conclusion, as the S&P 500 closes above 7,000.” This is the deck on the New York Times’ report on the S&P 500 hitting a new milestone, published on April 15. The report noted that the index crossed the 7,000 mark for the first time in history, and that it erased every point lost during the 40-day US-Iran conflict that rattled markets in February and March.
To many on Wall Street, the market can afford the luxury of overlooking the conflict in the Middle East because of blowout Q1 2026 earnings. For instance, Morgan Stanley’s Chief Investment Officer Mike Wilson said in an April 12 note that the 6,343 level that the S&P 500 touched on March 30 was a bull market correction and not a bear market. Wilson pointed to median earnings-per-share, or EPS, growth for S&P 500 companies running in the double digits, which is the fastest pace since 2021. The CIO also reiterated his forecast that earnings for S&P 500 firms will rise 17% in 2026, a call he told the New York Times on April 18 that he remains firm on, even as consumer confidence softens.
Incidentally, Goldman Sachs’ analysts beat Wilson to the punch on being bullish on US equities in spite of the US/Israel-Iran war. In late March, the analysts argued that the market’s recent sell-off, which was partly driven by the hostilities in the Middle East, had actually improved the near-term setup for US stocks. What the pullback did was ease investor positioning and reset expectations, which created a more balanced foundation for markets. Goldman reiterated its 12% S&P 500 earnings growth call for 2026.
This stance on earnings growth is also shared by the majority of analysts surveyed by the New York Times in the April 15 news story. The report detailed that these analysts expect Q1 2026 to be the sixth straight quarter of double-digit earnings growth. Even some are looking forward to the best earnings season in about five years.
Hardika Singh, a strategist at Fundstrat, told the Times that: “As corporate earnings are the biggest driver of stock returns, this level of steadfast earnings growth is an incredibly positive sign given that the market has been hammered in the first quarter by the effective closure of the Strait of Hormuz, which has sent oil prices skyrocketing to some of their highest levels in decades.”
With that in mind, this analysis identifies 10 stocks trading at or near 52-week highs that look best positioned to extend their run.
Our Methodology
To determine the 10 best 52-week high US stocks to buy, we used the Finviz stock screener to identify companies trading within 0%–10% of their 52‑week highs and have upside potential of at least 15% (as of April 21). We focused on companies that have recently had major news events. We also factored in hedge fund ownership using the Inside Monkey database. Finally, we ranked the stocks in ascending order based on the number of hedge funds holding positions as of Q4 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Best 52-Week High US Stocks to Buy
10. Enerflex Ltd (NYSE:EFXT)
Stock Price as of April 21: $23.79
52-Week Range: $6.36 – $24.08
Stock Upside Potential: 19.08%
Number of Hedge Fund Holders: 23
Enerflex Ltd (NYSE:EFXT) is among the best 52-week high US stocks to buy. On April 16, the equity research firm CIBC raised its price target on Enerflex Ltd stock to $25.50 from $16.75 and reiterated a Neutral rating on the shares. For this decision, the firm pointed to an upcoming catalyst for the company’s engineered systems bookings expected in Q1 2026. The catalyst relates to a previously announced data center project.
According to the firm, prospects of revenue growth from power generation projects will boost Enerflex’s valuation. Additionally, CIBC pointed out that increasing demand for natural gas and data center expansions will continue to support Enerflex’s services business.
However, CIBC also noted that Enerflex continues to generate a large chunk of its EBITDA from markets with elevated geopolitical risks. The firm reaffirmed its Neutral rating on Enerflex on the basis that it sees limited upside to the stock price target at the present level.
Also on April 16, RBC Capital named Enerflex Ltd among its top oil and gas services stocks. According to RBC Capital, Enerflex stands to realize many benefits from its acquisition of Exterran. First, it pointed out that the acquisition aligns with Enerflex’s strategy to expand its recurring revenue and high-margin footprint. Additionally, RBC Capital noted that the acquisition strengthens Enerflex’s business mix and expands its scope outside North America.
Enerflex Ltd, based in Alberta, Canada, is a global provider of energy infrastructure solutions. It offers products and services used in gas processing, power generation, refrigeration systems, and more. Its solutions are designed to ensure efficiency and reliability.
9. National Energy Services (NASDAQ:NESR)
Stock Price as of April 21: $23.82
52-Week Range: $5.47 – $26.85
Stock Upside Potential: 33.45%
Number of Hedge Fund Holders: 25
National Energy Services (NASDAQ:NESR) is among the best 52-week high US stocks to buy. On April 15, UBS named National Energy Services on its list of top oil and gas emerging opportunities stocks. According to the firm, National Energy Services is among the companies that stand to benefit from power generation demand, digital transformation, and regional activity improvements.
On its list, UBS focused on companies’ growth catalysts and operational advantages that position them well to drive performance in the evolving energy space. National Energy Services provides integrated oilfield services in North America, the Middle East, and the Asia-Pacific regions.
On March 16, National Energy Services announced that it had won $300 million in multi-year contract awards for cementing projects. The company said these contracts span five years and include projects in Kuwait and North Africa.
According to National Energy Services CEO Sherif Foda, these new contract awards solidify the company’s leading position in cementing. The executive also thanked their Kuwait clients for trusting National Energy Services with their projects.
Additionally, the executive noted that the contract awards in North Africa shows the company’s ability to expand quickly beyond its Gulf footprint. Foda added that this underscores the company’s growth potential in Libya and other African countries.
In its Q4 2025 financial report, National Energy Services revealed that revenue jumped 15.9% YoY to $398.3 million. It posted a net income of $7.8 million, and closed the year with $124.8 million in cash and cash equivalents.
National Energy Services is a major oilfield services provider in the MENA and Asia-Pacific regions. It helps clients with tasks such as hydraulic fracturing, cementing, coiled tubing, and more. The company, based in Houston, Texas, has 20 service lines and operates in more than 16 countries.
8. Spyre Therapeutics Inc (NASDAQ:SYRE)
Stock Price as of April 21: $73.39
52-Week Range: $12.28 – $75.00
Stock Upside Potential: 19.75%
Number of Hedge Fund Holders: 31
Spyre Therapeutics Inc (NASDAQ:SYRE) is among the best 52-week high US stocks to buy. On April 16, Spyre Therapeutics Inc said in a press release that it raised around $463.5 million in gross proceeds from its recent equity offering. The company offered 7.48 million shares of its common stock, and granted the underwriters the option to purchase an additional 975,000 shares. The underwriters fully exercised their option. The shares were offered at a price of $62 apiece, near the 52-week high.
Notably, Spyre’s equity raise adds to a solid cash position. At the end of 2025, Spyre had $757 million of cash, cash equivalents, and marketable securities. The company estimated that this cash would be enough to fund its operations into the second half of 2028.
On April 13, Raymond James launched coverage of Spyre Therapeutics Inc stock with a Strong Buy rating and a price target of $80. The firm pointed to the potential of Spyre’s clinical programs for its bullish view on the stock.
Spyre is developing next-generation, long-acting antibodies for inflammatory bowel disease and rheumatic diseases. The company says that around 2.4 million individuals in the US are diagnosed with inflammatory bowel disease. It says that more than 3 million people in the US are affected by rheumatic conditions.
Spyre has a pair of Phase 2 clinical trials in progress. Raymond James noted that proof-of-concept data readouts from these studies are expected in 2026 and 2027.
Spyre Therapeutics Inc is a US biotechnology company based in Waltham, Massachusetts. The company is focused on developing medicines for people living with inflammatory bowel disease and rheumatic diseases. It develops advanced antibodies engineered for prolonged activity and formulated for delivery as monotherapies.
7. Kodiak Sciences Inc (NASDAQ:KOD)
Stock Price as of April 21: $46.50
52-Week Range: $2.81 – $46.96
Stock Upside Potential: 44.32%
Number of Hedge Fund Holders: 34
Kodiak Sciences Inc (NASDAQ:KOD) is among the best 52-week high US stocks to buy. On March 27, H.C. Wainwright boosted its price target on Kodiak Sciences Inc to $58 from $38 and reiterated a Buy rating on the shares. The firm raised its price target after positive Phase 3 GLOW2 trial results for tarcocimab tedromer in diabetic retinopathy.
On March 26, Kodiak announced positive results from a Phase 3 trial of its experimental drug called Zenkuda (tarcocimab tedromer). Zenkuda is being evaluated as a treatment for patients with diabetic retinopathy. This is a diabetes-related eye complication that can result in a loss of vision. The company says that around 9.7 million people in the US live with diabetic retinopathy.
In that study, 62.5% of patients treated with Zenkuda showed at least a two-step improvement in retinopathy severity. That compared with 3.3% of patients who received a sham treatment. With that, Zenkuda met the main goal of the trial.
Additionally, Zenkuda showed superiority to sham treatment in a secondary endpoint. In this case, patients who received Zenkuda treatment showed an 85% reduction in the risk of developing sight-threatening complications.
In light of these trial results, H.C. Wainwright increased its probability of success for Zenkuda in diabetic retinopathy from 35% to 70%. Moreover, the firm raised its probability of success for Zenkuda and KSI-501 in wet age-related macular degeneration from 35% to 60%.
Kodiak Sciences Inc, based in Palo Alto, California, is a biopharmaceutical company focused on developing advanced therapies for retinal diseases. The company aims to improve on the existing therapies by offering next-generation medicines to help prevent blindness.
6. Century Aluminum Co (NASDAQ:CENX)
Stock Price as of April 21: $61.49
52-Week Range: $14.77 – $68.69
Stock Upside Potential: 27.46%
Number of Hedge Fund Holders: 46
Century Aluminum Co (NASDAQ:CENX) is among the best 52-week high US stocks to buy. On April 16, Century Aluminum Co announced that it had begun production at its expanded smelter plant in Mt. Holly, South Carolina. The company said that the expanded facility is expected to reach full production capacity by the end of June this year.
At full operation, the expanded Mt. Holly smelter will increase Century Aluminum’s primary aluminum production by 10%. This will strengthen the company’s leading position as the top primary aluminum producer in the US.
Century Aluminum plans to further expand its US production. In partnership with Emirates Global Aluminum, Century Aluminum plans to build a new aluminum smelter in Oklahoma. This plant would add 750,000 tonnes of primary aluminum production and double the current US production capacity.
Notably, Century Aluminum’s expansion efforts come amid the push to build a strong domestic supply chain of metals like aluminum.
On April 2, Century Aluminum applauded President Donald Trump’s executive order to fully enforce aluminum tariffs. The company noted that the new order would prevent aluminum importers from exploiting a valuation loophole to game the system at the expense of domestic manufacturers.
Century expects to report Q1 2026 adjusted EBITDA in the band of $215 million to $235 million. It expected the quarter to benefit from improved metal pricing. The company delivered adjusted EBITDA of $170.6 million in Q4.
Century Aluminum Co, headquartered in Chicago, Illinois, is a global metals company mainly focused on aluminum production. It has operations in the US, Iceland, the Netherlands, and Jamaica. Century Aluminum is the largest primary aluminum producer in the US.
5. Vaxcyte Inc (NASDAQ:PCVX)
Stock Price as of April 21: $61.91
52-Week Range: $28.09 -$65.00
Stock Upside Potential: 80.24%
Number of Hedge Fund Holders: 46
Vaxcyte Inc (NASDAQ:PCVX) is among the best 52-week high US stocks to buy. Vaxcyte Inc has completed enrollment in a pair of Phase 3 clinical trials evaluating its vaccine candidate VAX-31. The company announced this development on March 23, stating that it enrolled approximately 4,000 participants in the OPUS-1 trial and 1,300 in the OPUS-2 trial.
Vaxcyte’s vaccine candidate VAX-31 is intended to prevent invasive pneumococcal disease and pneumonia in adults. It’s also being tested in infants. The two Phase 3 trials that have completed enrollment are focused on adults.
In the OPUS-1 trial, VAX-31’s safety, tolerability, and immune response will be evaluated against two current standard pneumococcal vaccines. This study has two cohorts. It includes adults aged 50 years and older, and a separate group of adults aged 18 – 49 years. This study is being conducted at around 50 sites across the US, and its topline results are expected in Q4 2026.
The OPUS-2 trial will also evaluate the safety, tolerability, and immune response of VAX-31 in adults aged 50 and older. But in this study, they are assessing VAX-31 when administered alongside a licensed seasonal influenza vaccine. This is meant to be a descriptive study, and Vaxcyte said the results will inform a potential post-licensure outcomes study. The company is running the OPUS-2 trial at 25 sites across the US, and results are expected out in the first half of 2027.
At the end of 2025, Vaxcyte had $2.4 billion in cash. Then on February 24, the management disclosed that they had raised an additional $600 million in cash through equity financing to strengthen the company’s balance sheet and extend its cash runway.
Vaxcyte Inc, based in California, is a biotech company focused on developing advanced vaccines. It aims to offer solutions to prevent or treat bacterial diseases such as pneumonia. The company has several potential drugs in various development stages, with its most advanced drug candidates in Phase 3 trial stage.
4. Dianthus Therapeutics Inc (NASDAQ:DNTH)
Stock Price as of April 21: $91.42
52-Week Range: $16.64 – $96.50
Stock Upside Potential: 34.20%
Number of Hedge Fund Holders: 52
Dianthus Therapeutics Inc (NASDAQ:DNTH) is among the best 52-week high US stocks to buy. On March 26, William Blair reaffirmed an Outperform rating on Dianthus Therapeutics Inc stock. This action followed an FDA update on safety requirements for Dianthus Therapeutics’ claseprubart clinical trials.
In the safety update, the FDA has dropped antinuclear antibodies as screening criterion. Also, the regulator has removed the requirement for routine ANA testing during claseprubart clinical trials. These changes make it easier for Dianthus Therapeutics to enroll patients and run the trials.
Notably, Dianthus can now enroll patients into the claseprubart studies without screening and removing participants for ANAs. According to William Blair, the FDA decision may have a positive impact on the potential drug’s labeling.
The firm noted that the CAPTIVATE trial interim responder analysis met its best-case scenario. As a result, William Blair believes claseprubart has a differentiated product profile.
Claseprubart is being developed as a potential therapy for various autoimmune disorders in areas with unmet needs. Dianthus Therapeutics plans to initiate a Phase 3 trial of claseprubart in patients with gMG in mid-2026. It expects topline results from this study in the second half of 2028.
A Phase 2 trial of claseprubart in patients with MMN is ongoing, with topline results expected in the second half of 2026. Also, the company expects to provide an update on topline guidance for Part B of the CAPTIVATE trial by the end of 2026.
Dianthus Therapeutics Inc is an American biotech company focused on developing best-in-class antibody therapeutics. Its work is focused on therapies for patients living with severe autoimmune diseases to address unmet medical needs.
3. Xenon Pharmaceuticals Inc (NASDAQ:XENE)
Stock Price as of April 21: $56.48
52-Week Range: $28.19 – $63.95
Stock Upside Potential: 27.01%
Number of Hedge Fund Holders: 55
Xenon Pharmaceuticals Inc (NASDAQ:XENE) is among the best 52-week high US stocks to buy. On April 19, Xenon Pharmaceuticals Inc presented data from the Phase 3 X-TOLE2 study of its epilepsy drug candidate, azetukalner, at the American Academy of Neurology Annual Meeting in Chicago.
Xenon used the event to highlight the study’s strong results. It also used the platform to talk about its plans to seek regulatory approval for azetukalner.
In the late-stage study, patients treated with azetukalner showed a 53.2% reduction in monthly seizure frequency at the 25 mg dose. At the 15 mg dose, the monthly seizure frequency reduced by 34.5%. Those in the placebo group showed a 10.4% reduction.
Some patients achieved complete seizure control. Xenon revealed that the rate of 100% seizure reduction increased over time as patients remained in the therapy. In the final four weeks of the trial, 13.7% of patients in the 25 mg group and 12.8% of those in the 15 mg group achieved complete seizure control. That compared to 4.0% for the placebo group.
The study enrolled patients with treatment-resistant epilepsy who had around 12.75 seizures per month and had tried around five anti-seizure medications before.
Xenon plans to file for FDA approval of azetukalner in Q3 2026, with a decision expected in late 2027 or early 2028. On March 9, Reuters reported that analysts were estimating over $2 billion in peak sales for azetukalner if approved.
Xenon Pharmaceuticals Inc is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders, including epilepsy and depression. It has several potential drug products in the pipeline. The company is based in Canada, but it also has offices in the US.
2. Terawulf Inc (NASDAQ:WULF)
Stock Price as of April 21: $20.53
52-Week Range: $2.65 – $20.98
Stock Upside Potential: 39.82%
Number of Hedge Fund Holders: 62
Terawulf Inc (NASDAQ:WULF) is among the best 52-week high US stocks to buy. On April 16, Keefe, Bruyette & Woods reaffirmed its Outperform rating and $23 price target on Terawulf Inc stock. This action followed Terawulf’s equity offering to raise funds for projects and potential acquisitions. The company said it raised around $900 million in gross proceeds after issuing 47.4 million shares at $19.00 apiece. It upsized the offering from an initial target to raise $800 million.
Keefe views this equity raise by Terawulf as net positive. Terawulf said that it plans to use the proceeds from the offering to fund the construction of its planned data center campus in Hawesville, Kentucky. This would include the repayment of outstanding amounts under its bridge credit facility. Moreover, the company intends to use the funds for future site acquisitions and for general corporate purposes.
According to Keefe, the capital raise pre-funds the Hawesville data center project and removes uncertainty around post-leasing financing. The firm also noted the timing of the equity offering, pointing out that it comes as the stock trades close to its 52-week high, which indicates strong investor confidence.
Terawulf released its preliminary Q1 2026 results on April 14. The report revenue is expected in the range of $30 million to $35 million, and adjusted EBITDA is expected in the band of $0 million to $3 million. Terawulf closed Q1 with $3.1 billion in cash and $5.8 billion in debt.
Terawulf Inc is an American digital infrastructure company. It builds and operates industrial-scale data centers designed for high-performance computing hosting, AI workloads, and bitcoin mining. It specializes in providing low-carbon compute capacity.
1. ASML Holding NV (NASDAQ:ASML)
Stock Price as of April 21: €1,480.17
52-Week Range: €651.46 – €1,547.22
Stock Upside Potential: 20.43%
Number of Hedge Fund Holders: 101
ASML Holding NV (NASDAQ:ASML) is among the best 52-week high US stocks to buy. On April 16, Goldman Sachs increased its price target on ASML Holding NV to €1,570 from €1,450 while reiterating a Buy rating on the stock. For this action, Goldman Sachs pointed to the company’s strong Q1 2026 results and upbeat full-year 2026 outlook.
ASML released its Q1 results on April 15. The report showed net sales were €8.77 billion, above the consensus estimate of €8.5 billion. Net income of €2.76 billion also surpassed the consensus expectation of €2.54 billion.
The company boosted its full-year 2026 net sales projection to a range of €36 billion to €40 billion. The prior forecast called for net sales of €34 billion to €39 billion. ASML expects its 2026 gross margin to be between 51% and 53%. ASML supplies machines used for producing chips, including advanced chips for AI workloads.
In light of ASML’s Q1 results and 2026 guidance, Goldman Sachs raised its 2026-2030 revenue estimates for the company by 6% to 10%. Moreover, the investment bank boosted its gross profit estimates for ASML for the 2026-2030 period by 6% to 10%.
According to Goldman Sachs, ASML stands to benefit from continued strong demand for advanced chips and memory to power AI systems and other high-performance computing needs.
ASML Holding NV is a Dutch company that provides machines for manufacturing semiconductor chips. It supplies these machines to the world’s leading chipmakers like Intel, TSM, and Samsung. ASML’s manufacturing technology makes it possible to produce smaller chips at a faster rate and more efficiently.
READ NEXT: 9 Must-Buy Penny Stocks to Invest In Now and 10 Best AI Stocks to Buy Under $25.
